Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...

Aficamten offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed aficamten's efficacy in improving exercise ...

What Is Myqorzo, and Why Does It Matter? Myqorzo (aficamten) is a new oral medicine approved by the FDA for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). It relieves symptoms ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved aficamten to improve functional capacity and symptoms in adults with obstructive hypertrophic ...

Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...

Credit: Getty Images Early recognition and management of obstructive sleep apnea are critical to preventing cardiovascular, cognitive, and metabolic complications in older adults. Screening for OSA ...

Maybe you know you snore like a bear, but you don’t feel much urgency to look into it. Or maybe you have been told to wear a continuous positive airway pressure, or CPAP, machine for sleep apnea, but ...

For the first time, researchers have shown that tackling obstructive sleep apnea’s two root causes at once, using both oxygen and a jaw-forwarding device, can dramatically cut breathing interruptions ...

Anyone can develop obstructive sleep apnea (OSA), but there are certain risk factors that can make some people more susceptible to the condition than others. “Obesity, by far, is the main risk factor, ...

Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...

MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...